Generic medications: Another variable in the treatment of illnesses

Journal of Psychopharmacology

Volumn 21, Issue 5, 2007, Pages 459-460

  Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG; LITHIUM;

BIOEQUIVALENCE; CONSUMER; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; PATIENT CARE; PRIORITY JOURNAL; SEIZURE;

ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; GUIDELINES; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY CONTROL; THERAPEUTIC EQUIVALENCY; TRANQUILIZING AGENTS;

EID: 34547104598     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107081126     Document Type: Editorial

References (18)

1. Blakesley V.A. (2005) Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J 7: E42 - E46
2. Borgheini G. (2003) The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25: 1578 - 1592
3. CanadaDrugs.com (2006) Brand vs. Generic. Available at www.canadadrugs.com (accessed 21 November 2006 )
4. Canadian Generics Pharmaceutical Association (2006) Brand Name Drugs vs. Generic Drugs: What's the Difference? Available at http://www.canadiangenerics. ca/en/resource/BrandvsGeneric-What%27stheDifference.pdf (accessed 21 November 2006 )
5. Canadian Health Protection Branch (HPB) (1992) Drugs Directorate Guidelines Conduct and analysis of bioavailability and bioequivalence studies - Part A: oral dosage formulations used for systemic effects. Page 6, http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/bio/ fedstate_sujetsjeun_e.html
6. Committee for Proprietary Medicinal Products (CPMP) (1991) Working Party on on Efficacy of Medicinal Products. Note for guidance: investigation of bioavailablility and bioequivalence. Pharmacol Toxicol 68: 75 - 76
7. Food and Drug Administration (FDA) - Centre for Drug Evaluation and Research (CDER) (2000) Guidance for Industry - Levothyroxine sodium tablets - in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. Available at http://www.fda.gov/default.htm. (accessed 3 January 2007 )
8. Food and Drug Administration (FDA), Centre for Drug Evaluation and Research (CDER) (1992) Guidance for Industry: statistical procedures for bioequivalence studies using a standard two-treatment crossover design, http://www.fda.gov/Cder/guidance/3616fnl.pdf
9. Gervasoni M., Pirola R., Bareggi S.R., Tonello C., Nisoli E., Vialba L. (2004) The bioequivalence and therapeutic efficacy. Clin Ther 26: 801 - 802
10. Meyer M.C. (2001) United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 62 Suppl 5: 4 - 9
11. Office of the Auditor General of Canada (2006) Allocating funds to Regulatory Programs - Health Canada. November 2006 Report. Availableatwww.oag- bvg.gc.cachapter8,8.23 (accessed 11 November 2006 )
12. Opelz G. (2001) CTS Collaborative Transplant Study, Newsletter 1: 2001. Available at http://www.ctstransplant.org (accessed 5 January 2007 )
13. Qazi Y.A., Forrest A., Tornatore K., Venuto R.C. (2006) The clinical impact of 1:1 conversion from neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant 20: 313 - 317
14. Rosenbaum D.H., Rowan A.J., Tuchman L., French J.A. (1994) Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 35: 656 - 660
15. Smith J.C., Tarocco G., Merazzi F., Salzmann U. (2006) Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr Med Res Opin 22: 709 - 720
16. Taber D.J., Baillie G.M., Ashcraft E.E., Rogers J., Lin A., Afzal F., Baliga P., Rajagopalan P.R., Chavin K.D. (2005) Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 80: 1633 - 1635
17. The European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use (2001) Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Page 5, http://www.emea.europa.eu/pdfs/ human/ewp/140198en.pdf
18. Van Ameringen M, Mancini C., Patterson B., Bennett M. (2007) Symptom relapse following switch from Celexa to generic citalopram. J Psychopharm 21: 472 - 476